| scholarly article | Q13442814 |
| P2093 | author name string | Andrew H Talal | |
| Bryce D Smith | |||
| Steven Kritz | |||
| Roberto Zavala | |||
| Jon E Zibbell | |||
| Marija Zeremski | |||
| Melissa Lin | |||
| Rositsa B Dimova | |||
| P2860 | cites work | Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews | Q24630669 |
| Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis | Q26822903 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment | Q31870680 | ||
| Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services | Q33277431 | ||
| Barriers to the treatment of hepatitis C. Patient, provider, and system factors | Q34723678 | ||
| Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada | Q34789013 | ||
| Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States | Q35008495 | ||
| Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States | Q35737654 | ||
| Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 | Q36100389 | ||
| Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing | Q36272520 | ||
| Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. | Q36376962 | ||
| Offers of hepatitis C care do not lead to treatment | Q36440941 | ||
| Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance | Q37002923 | ||
| Limited uptake of hepatitis C treatment among injection drug users | Q37238205 | ||
| Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care | Q37358615 | ||
| Hepatitis C virus infection in USA: an estimate of true prevalence | Q37899936 | ||
| The role of resistance in HCV treatment | Q38063998 | ||
| Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. | Q38103677 | ||
| Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. | Q39688624 | ||
| Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. | Q39820916 | ||
| HIV and HCV health beliefs in an inner-city community | Q39955005 | ||
| Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults | Q42271736 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. | Q42978282 | ||
| Injection drug users: the overlooked core of the hepatitis C epidemic | Q43234059 | ||
| Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs | Q44105883 | ||
| Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. | Q45497809 | ||
| Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale | Q46062606 | ||
| Knowledge of and interest in hepatitis C treatment at a methadone clinic | Q48494486 | ||
| Knowledge of hepatitis among active drug injectors at a syringe exchange program | Q81889849 | ||
| Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel | Q82303359 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 249-257 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Journal of Addiction Medicine | Q15752435 |
| P1476 | title | Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance | |
| P478 | volume | 8 |
| Q99571275 | A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South |
| Q90026182 | Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City |
| Q40144817 | Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia |
| Q36079814 | Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. |
| Q51744985 | Hepatitis C Virus Knowledge Among Pregnant Women with Opioid Use Disorder. |
| Q35961748 | Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders |
| Q57144432 | Hepatitis C virus prevention and care for drug injectors: the French approach |
| Q38907436 | High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs |
| Q57178901 | Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention |
| Q92932920 | Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial |
| Q56342192 | Knowledge of Hepatitis C Risk Factors is Lower in High Incidence Regions |
| Q38873165 | Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals |
| Q40306589 | Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders |
| Q33853664 | Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. |
| Q57171449 | Perception of Hair Loss and Education Increases the Treatment Willingness in Patients With Androgenetic Alopecica: A Population-Based Study |
| Q45324716 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results |
| Q37423218 | Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment |
Search more.